Developing a vaccine for a serious childhood illness caused by a virus.
Official title: Advanced Development of a Vaccine for Acute Flaccid Myelitis Associated with Enterovirus D68
Funded at Intravacc B.v. · NIH-11250792 · Data updated 2026-11-12
This study is working on a new vaccine to help protect children from Acute Flaccid Myelitis (AFM), a serious condition linked to a virus, and it aims to eventually test the vaccine's safety and effectiveness in kids.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intravacc B.v. NIH-funded |
| Lab location | 1 site (Bilthoven, Netherlands) |
| Project start | September 1, 2020 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,004,130 |
| NIH project number | 75N93020C00037-P00011-9999-1 |
| Project ID | NIH-11250792 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are children who are at risk of developing Acute Flaccid Myelitis due to Enterovirus D68 infections.
✕Less likely to help
Patients who are adults or those who do not have a history of Enterovirus D68 infections may not receive benefit from this research.
What this research studies
This research focuses on creating a vaccine specifically for Acute Flaccid Myelitis (AFM), a rare but severe condition that affects children and is associated with the Enterovirus D68. The project involves formulating and manufacturing vaccine components, conducting stability tests, and performing efficacy assessments using animal models. It aims to advance to early-stage clinical trials to evaluate the vaccine's safety and effectiveness in pediatric populations. The ultimate goal is to provide a preventive measure against AFM outbreaks.
Why it matters
Potential benefit: If successful, this research could provide a vaccine that protects children from Acute Flaccid Myelitis, potentially reducing the incidence of this debilitating condition.
How similar studies have gone: Other research has shown promise in developing vaccines for viral infections, indicating that this approach has potential for success.
Where this research is happening
-
Intravacc B.v.
Bilthoven, Netherlands Active
Researchers
- Principal investigator: Oosterhoff, Dinja — Intravacc B.v.
- Study coordinator: Oosterhoff, Dinja
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.